OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

ID#: NCT07136012

Age: 50 - 105 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: August 22, 2025

End Date: October 20, 2031

Contact Information:
Amgen Call Center
866-572-6436
Summary: The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Eligibility:

Inclusion Criteria:

- Age ≥50 years

- Lp(a)≥ 200 nmol/L during screening

- Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

Exclusion Criteria:

- Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)

- Prior or planned arterial revascularization

- History of major bleeding disorder
Find a Clinical Trial Find Cancer Clinical Trials